肺炎疫苗比較

Moderna reported that during the phase 3 study of its vaccine candidate mRNA-1273which enrolled 30,000 adult U.S. participants, just five of the 95 COVID-19 cases occurred among the vaccinated, while 90 infections were identified in the placebo group. This corresponds to an efficacy of 94.5%. None of the infected patients who received the vaccine developed severe COVID-19, while 11 (12%) of those who received the placebo did.

Similarly, the Pfizer-BioNTech vaccine candidate, BNT162b2, was 90% effective in preventing infection during the phase 3 clinical trial, which enrolled 43,538 participants, with 30% in U.S. and 42% abroad.


發表迴響

您的電子郵件位址並不會被公開。 必要欄位標記為 *

*

Blue Captcha Image
Refresh

*

* Copy this password:

* Type or paste password here:

8,860 Spam Comments Blocked so far by Spam Free Wordpress

您可以使用這些 HTML 標籤與屬性: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>